{"filings":[{"id":91791,"accession_number":"0001628280-26-028386","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crescent Biopharma Q1 net loss $23.3M; cash $189.2M funds ops into 2028","event_type":"earnings","confidence":"high","bullets":["Net loss $23.3M ($0.70/sh) vs $15.1M ($19.63/sh) in Q1 2025; revenue $1.0M from Kelun-Biotech license.","R&D expenses $17.9M (up 69% YoY) on CR-001/CR-002 development; G&A $7.9M (up 119% YoY).","Cash $189.2M as of March 31, 2026; expected to fund operations into 2028.","CR-001 ASCEND trial enrollment ongoing; proof-of-concept data expected Q1 2027.","CR-002 IND submission on track for mid-2026; clinic entry H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1039000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102132,"accession_number":"0001628280-26-011988","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crescent Biopharma reports FY2025 net loss $153.9M, revenue $10.8M; cash $213.2M","event_type":"earnings","confidence":"high","bullets":["Net loss of $92.4M ($4.01 per share) for Q4 2025 vs. $15.2M in prior year; FY net loss $153.9M.","Revenue of $10.8M in 2025 from $20M upfront from Kelun-Biotech license deal; no revenue in 2024.","R&D expenses surged to $138.1M in FY2025 (vs. $14.0M in 2024) driven by CR-003 license payment and pipeline costs.","Cash and equivalents $213.2M at Dec 31, 2025; expected to fund operations into 2028 after $185M private placement.","Strategic partnership with Kelun-Biotech for CR-001 (PD-1 x VEGF) and CR-003 (ITGB6 ADC); ASCEND Ph1/2 trial dosed first patient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":10844000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118447,"accession_number":"0001628280-25-055221","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Crescent Biopharma partners with Kelun-Biotech on CR-001/SKB105, raises $185M","event_type":"other_material","confidence":"high","bullets":["Licenses CR-001 to Kelun-Biotech for Greater China; receives $20M upfront and up to $30M milestones.","In-licenses SKB105 (ADC) from Kelun for ex-China markets; pays $80M upfront and up to $1.25B milestones.","Private placement of ~$185M at $13.41/share, led by Jefferies and others; closing expected Dec 8, 2025.","Cash runway extended into 2028; Phase 1/2 monotherapy trials for CR-001 and SKB105 expected Q1 2026.","Pipeline milestones set through 2027; combination trials of CR-001 with ADCs planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118446,"accession_number":"0001628280-25-049865","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crescent Bio Q3 net loss $24.6M; cash $133.3M; CR-001 IND on track","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.6M ($1.27 per share) for Q3 2025; R&D expense $20.3M, G&A $5.5M.","Cash position $133.3M as of Sept 30, 2025, expected to fund operations through 2027.","IND submission for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; Phase 1 start Q1 2026.","Preclinical data for CR-001 presented at SITC showing cooperative pharmacology and anti-tumor activity.","ADC program CR-002 IND submission expected mid-2026; CR-003 also advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134883,"accession_number":"0001628280-25-036846","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Crescent Biopharma Q2 net loss $21.8M; merger & $200M financing closed","event_type":"earnings","confidence":"high","bullets":["Net loss $21.8M ($4.93/share) for Q2 2025; R&D $12.1M, G&A $8.9M.","Cash $152.6M as of June 30, 2025, expected to fund operations through 2027.","Completed merger with GlycoMimetics and closed $200M private financing.","IND for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; proof-of-concept data H2 2026.","Adopted Executive Severance Plan with change-in-control benefits for executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151840,"accession_number":"0001104659-25-060714","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["1.01","2.01","5.02","9.01","2.02","3.03","4.01","5.01","5.03","5.05","5.06","7.01"],"status":"ready","headline":"Crescent Biopharma completes reverse merger with GlycoMimetics; post-merger shares trade under CBIO","event_type":"m_and_a","confidence":"high","bullets":["Former GlycoMimetics securityholders own ~2.7% of combined company; Crescent holders own ~97.3% on fully diluted basis.","Crescent raised ~$200M gross proceeds via pre-closing financing: 85.5M shares and 19.1M pre-funded warrants.","Exchange ratio set at 0.1445 GlycoMimetics shares per Crescent share; 1-for-100 reverse stock split effected.","Combined company has ~19.5M shares outstanding (including warrants and convertible preferred) post-merger.","Company name changed to Crescent Biopharma, Inc.; stock trades under symbol CBIO on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151839,"accession_number":"0001104659-25-057078","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Stockholders approve merger with Crescent Biopharma; 1-for-100 reverse split","event_type":"other_material","confidence":"high","bullets":["Stockholders approved all 10 proposals including merger agreement, stock issuance, charter amendments, reverse split, and equity plans.","Board approved 1-for-100 reverse stock split; outstanding shares reduced from ~64.5M to ~0.6M.","Post-merger combined company to trade as Crescent Biopharma, Inc. (CBIO) on Nasdaq starting June 16, 2025.","Combined company expected to have ~14.8M shares outstanding (~25.3M fully diluted) post-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151838,"accession_number":"0001104659-25-054587","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GlycoMimetics supplements merger disclosures; clarifies Crescent selection, $125M PIPE","event_type":"m_and_a","confidence":"high","bullets":["GlycoMimetics chose Crescent over Party A (Chinese parent) due to regulatory clearance timing risks.","Transaction terms: $8M enterprise value for GLYC, $50M for Crescent, $125M concurrent PIPE.","No GlycoMimetics executives will be retained or receive equity post-closing; no financial projections made.","Term Sheet Committee formed with Mr. Junius and Mr. Pearson; dissolved after Merger Agreement execution.","Supplemental tables update precedent IPOs, public companies, M&A, and reverse merger comparisons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151837,"accession_number":"0001104659-25-040386","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GlycoMimetics amends Crescent merger; exchange ratio ~15.42 GLYC shares per Crescent share","event_type":"m_and_a","confidence":"high","bullets":["Amendment clarifies Crescent RSUs will be assumed using the same exchange ratio as other Crescent securities.","Each Crescent share to receive approximately 15.4192 shares of GlycoMimetics common stock.","Post-merger, GlycoMimetics holders expected to own ~2.6%; Crescent holders ~97.4% (fully diluted).","GlycoMimetics net cash at closing assumed at $1.8 million for ownership calculation.","Certificate of Designation for Series A Non-Voting Preferred Stock updated to clarify voting mechanics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170708,"accession_number":"0001558370-25-001517","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.02","5.02"],"status":"ready","headline":"GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart","event_type":"other_material","confidence":"high","bullets":["Apollomics terminated the collaboration license for uproleselan and GMI-1687 in China, effective 90 days from Feb 19, 2025.","CEO Harout Semerjian and CFO Brian Hahn ceased employment on Feb 21, 2025; severance payments of $1,365,456 and $480,991 respectively.","Five directors (Goldberg, Jackson, King, Koenig, Semerjian) resigned Feb 21, 2025; no disagreement with company operations.","Semerjian consulting: $700/hr for 12 months; Hahn consulting: $15,000/month through change in control or Sep 30, 2025.","Company is pursuing a merger with Crescent Biopharma (Form S-4 filed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170707,"accession_number":"0001558370-25-001016","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities","event_type":"m_and_a","confidence":"high","bullets":["Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.","Exchange ratio ~14.9149 Crescent shares per GLYC share; based on Sep 30 caps.","A&R Purchase Agreement: $200M Crescent securities purchased pre-closing, replacing post-closing GLYC financing.","Amendment adjusts filings; S-4 registration statement and company stockholder approval sequence updated.","Condition: GLYC net cash at closing must be ~$1.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}